Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Trial Results
Anatara Lifesciences has completed Stage 2 of its Phase II GaRP-IBS trial, confirming no safety concerns and a sustained reduction in IBS-SSS scores by over 40% in the treatment group, though not statistically significant compared to placebo.
Secondary Endpoints
The trial achieved significant improvements in anxiety scores (P=0.034) while depression scores remained stable. Internal analyses showed promising trends in pain and abdominal distension relief among participants.
Executive Comments
Dr David Brookes, Executive Chair, stated, “Following the formal independent statistical analysis, the Company has undertaken an extensive review of the trial data and procedures to ensure nothing has been overlooked in assessing the potential of the GaRP product. We have been very encouraged by the results of our internal review of the data when looking at subgroups and through the various scoring systems. It is pleasing to share these results, which will form the basis for any potential commercial interactions, as the treatment arm clearly outperforms the placebo when assessing symptom relief of pain and distension. Those who were involved are very much appreciated as this was a challenging trial and our review suggests that a simpler scoring system may have enhanced the experience and the results.”
Future Outlook
Anatara is formalising the GaRP project’s value for potential commercial discussions and progressing its Anti-Obesity Project with ongoing pre-clinical studies set to complete within six months.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
